Acemetacin

Summary

Acemetacin (CHEMBL189171) is an approved small-molecule prodrug (ATC M01AB11); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AB11
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 415.8 Da · C21H18ClNO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL189171
Name	Acemetacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	1981
ChEBI	CHEBI:31162
ATC	M01AB11
Molecular formula	C21H18ClNO6
Molecular weight	415.8
InChIKey	FSQKKOOTNAMONP-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O

IUPAC name: 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid

ChEBI definition: A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin.

Pharmacological roles (ChEBI): prodrug, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, non-steroidal anti-inflammatory drug, non-narcotic analgesic.

Also known as: Acemetacin, Acemetacina, Acemetacine, Emflex, NSC-757413, Rantudil, SID11112782, SID26746953, SID855677, SID124882621, ACEMETACIN, ACEMETACINE

Patent coverage: 4,079 distinct patent families (17,027 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 16,940 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Pyruvate kinase PKM, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, 5-hydroxytryptamine receptor 1A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Lactoylglutathione lyase, Cruzipain, Prostaglandin G/H synthase 1, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 15 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	8	IC50	10	nM	CHEMBL_ACT_25553878
PTGS2	8	IC50	10	nM	CHEMBL_ACT_25553880
HIF1A	7	Potency	100	nM	CHEMBL_ACT_4128009
HIF1A	7	Potency	100	nM	CHEMBL_ACT_4520618
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4127924
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4520533

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07582146	PHASE4	NOT_YET_RECRUITING	Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).